Group 1 - The core event was the bio-manufacturing industry promotion conference held in Shizuishan, Ningxia, where multiple bio-manufacturing projects were signed [1][5] - The signed projects include an annual production of 5,000 tons of DHA/EPA algae oil, bio-based dodecanedioic acid, and 20,000 tons each of butyric acid cellulose and cellulose acetate, totaling nine industrial projects [6][1] - Ningxia has also signed industry-university-research cooperation projects with Tianjin University of Science and Technology and the China Textile Science Research Institute to promote the transformation of scientific and technological achievements [7][1] Group 2 - Experts and representatives from Tianjin University of Science and Technology and the Institute of Microbiology of the Chinese Academy of Sciences shared insights on the forefront trends, research applications, and industrialization paths of bio-manufacturing technology during the conference [9][3] - Ningxia is focusing on bio-manufacturing as a key area for cultivating new productive forces, with Shizuishan as the core area and Yinchuan focusing on the health sector [9][3] - Shizuishan has a solid industrial foundation, complete industrial support, and competitive factor guarantees, especially with the successful selection of the "Ningke Bio-based Long Carbon Chain Material Pilot Platform" as one of the first national bio-manufacturing pilot capacity construction platforms by 2025, providing strong support for the development of the bio-manufacturing industry [9][3] Group 3 - Shizuishan is formulating special policies to support the bio-manufacturing industry through optimization of approvals, platform construction, remote research and development, talent introduction, and financial support [9][3] - A distinctive plan is to establish an "Eastern R&D, Shizuishan pilot and mass production" industrial collaborative model, with intergovernmental cooperation already reached with relevant cities and counties in Hunan to attract external resources [9][3] - Ningxia has formed a certain industrial chain, with companies like Ningxia Zhongke Bio-New Materials Co., Ltd. achieving large-scale production of bio-based long carbon chain new materials, breaking the traditional reliance on petrochemical pathways [4][3]

Core Viewpoint - Ningxia Zhongke Biological Technology Co., Ltd. is facing significant financial distress, having been ruled by the court to terminate its restructuring process and enter the execution phase of its restructuring plan, which poses a risk of bankruptcy if the plan is not executed successfully [2][5][9]. Group 1: Financial Performance - The company reported a net profit attributable to shareholders of -53.89 million yuan for the year 2024, with a net profit of -40.47 million yuan after deducting non-recurring gains and losses [3][7]. - For the third quarter of 2025, the company achieved an operating income of 32.74 million yuan, with a net profit attributable to shareholders of -25.10 million yuan and a net asset value of -17.92 million yuan [3][7]. Group 2: Regulatory Actions - The company received an administrative penalty from the China Securities Regulatory Commission (CSRC) on April 3, 2025, which has led to additional risk warnings on its stock according to the Shanghai Stock Exchange regulations [4][8]. - The stock has been under other risk warnings since April 8, 2024, due to the suspension of operations at its subsidiary, Zhongke New Materials, which has recently resumed production but remains uncertain regarding sustainable operational capacity [2][7]. Group 3: Market Activity - The company's stock has experienced a continuous trading halt for seven consecutive trading days, with a cumulative increase of 40.49% [4][10]. - Despite the recent stock price volatility, the company's fundamental situation has not changed significantly, and there are no undisclosed major information [4][10].

Core Viewpoint - Ningxia Zhongke Biotechnology Co., Ltd. is currently undergoing a restructuring plan, which may lead to a significant downward adjustment in its stock price due to potential capital reserve increases and other factors [2][3]. Group 1: Stock Price Risks - The company has indicated that its stock price may experience a downward adjustment of approximately 30% following the implementation of the restructuring plan, based on the closing price on December 3, 2025 [2][3]. - The adjustment in stock price will depend on the relationship between the closing price on the capital reserve increase registration date and the average price of the newly issued shares [3]. Group 2: Restructuring Uncertainties - The company has been ruled by the court to terminate the restructuring process and enter the execution phase of the restructuring plan, which carries the risk of being declared bankrupt if the plan is not executed [4]. - If the company is declared bankrupt, it will undergo liquidation, and its stock may face delisting according to the Shanghai Stock Exchange listing rules [4]. Group 3: Additional Risks - There are risks associated with the pre-restructuring investment agreements that have been signed, which may be terminated or become unenforceable [5]. - Other companies under the same group, such as Ningxia Zhongke New Materials Co., Ltd. and Ningxia Xinhai Hengli International Trade Co., Ltd., are also facing similar restructuring challenges and potential bankruptcy risks [6].

Core Viewpoint - *ST Ningke (600165.SH) and its subsidiaries have received court approval for their restructuring plans, marking a significant step in their financial recovery process [1] Group 1: Company Restructuring - The company and its subsidiaries, Ningxia Zhongke Biological New Materials Co., Ltd. and Ningxia Xinhai Hengli International Trade Co., Ltd., have been granted approval for their respective restructuring plans by the Shizuishan Intermediate People's Court [1] - The court's decision includes the termination of the restructuring procedures for the company and its subsidiaries, indicating a potential stabilization in their operations [1]

Core Viewpoint - *ST Ningke (600165.SH) and its subsidiaries have received court approvals for their restructuring plans, marking the end of their restructuring processes [1] Group 1 - The company and its subsidiaries, Ningxia Zhongke Biological New Materials Co., Ltd. and Ningxia Xinhai Hengli International Trade Co., Ltd., received civil rulings from the Intermediate People's Court of Shizuishan, Ningxia Hui Autonomous Region [1] - The court approved the restructuring plans for Ningxia Zhongke Biotechnology Co., Ltd., Ningxia Zhongke Biological New Materials Co., Ltd., and Ningxia Xinhai Hengli International Trade Co., Ltd. [1] - The restructuring procedures for the company and its subsidiaries have been terminated following the court's decision [1]

证券代码：600165 股票简称：ST 宁科 公告编号：临 2025-086 宁夏中科生物科技股份有限公司 关于公司及子公司完成法人变更并换领营业执照的公告 类 型：股份有限公司（上市、自然人投资或控股） 法定代表人：符杰 注册资本：陆亿捌仟肆佰捌拾捌万叁仟柒佰柒拾伍圆整 成立日期：1998 年 05 月 14 日 住 所：宁夏石嘴山市惠农区河滨街 经营范围：许可项目：肥料生产（依法须经批准的项目，经相关部门批准后 方可开展经营活动）一般项目：生物基材料技术研发；生物基材料制造；生物基 材料销售；生物有机肥料研发；肥料销售；生物基材料聚合技术研发；生物化工 产品技术研发；新材料技术研发；工程塑料及合成树脂制造；合成材料制造（不 含危险化学品）；工程塑料及合成树脂销售；合成材料销售；工程和技术研究和 试验发展；新材料技术推广服务；技术服务、技术开发、技术咨询、技术交流、 技术转让、技术推广；技术进出口；化工产品销售（不含许可类化工产品）（除 许可业务外，可自主依法经营法律法规非禁止或限制的项目） 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性 ...

Transaction Overview - The company approved the transfer of a 10% stake in Ningxia Zhongke Biological New Materials Co., Ltd. from Shizuishan Zhengxingcheng New Materials Technology Partnership for a total consideration of RMB 106 million [1] - The company failed to pay the remaining transfer amount within the stipulated 60 working days, leading to a supplementary agreement allowing payment by October 31, 2022 [2] Debt Settlement Agreement - Due to the outstanding payment, the company was required to pay a penalty of 0.05% per day on the unpaid amount until settled [3] - On November 23, 2023, the company approved a debt settlement agreement using a property as payment for the remaining transfer amount [3] - The company later decided to terminate the debt settlement agreement on December 5, 2023, considering its business development and financial arrangements [3] Property Transfer and Management - The company signed a property holding agreement to ensure the property remains an asset of the company despite the termination of the debt settlement agreement [3] - The company is unable to transfer back the property due to tax payment issues, which are a result of financial constraints [4] - As of the announcement date, the property has been transferred back to the company, and the property holding agreement has been terminated [4][5]

Core Viewpoint - Ningxia Zhongke Biotechnology Co., Ltd. is facing significant financial distress, with a total debt of 2.236 billion yuan, including overdue debts of 1.81 billion yuan and litigation-related debts of 1.84 billion yuan, leading to a severe impact on its ability to continue operations [1][5]. Debt and Financial Situation - As of the announcement date, the company's total debt stands at 2.236 billion yuan, with overdue debts totaling 1.81 billion yuan and litigation-related debts amounting to 1.84 billion yuan [1][5]. - Most of the company's bank accounts, except for those of its subsidiaries, are frozen, indicating a critical liquidity crisis [1][5]. - The company lacks sufficient funds and liquid assets to meet its debt obligations, raising concerns about its ability to continue as a going concern and potential bankruptcy [1][5]. Litigation Status - The company and its subsidiaries have been involved in multiple lawsuits over the past 12 months, with various stages including concluded, executed, and pending cases [2]. - The total amount involved in the current litigation is approximately 8.7 million yuan, along with associated litigation and preservation costs [2]. - The company is currently a defendant in several lawsuits related to loan agreements, equity transfer disputes, sales contracts, construction contracts, and securities fraud claims [2][5]. Specific Case Details - A specific lawsuit has been filed by Yantai Jiuqi Construction Engineering Installation Co., Ltd. against the company and Shandong Guiyuan Biotechnology Co., Ltd. for unpaid construction fees totaling 3.699 million yuan [2][3]. - The lawsuit is based on a construction contract where the plaintiff claims that the defendants have delayed payment for completed work [3]. Impact on Future Profitability - Due to the ongoing litigation and the current financial situation, it is difficult to accurately assess the impact on the company's current and future profitability [4][5].

Core Viewpoint - The article discusses the announcement of a project by Ningxia Zhongke Biological New Materials Co., Ltd. to produce 110,900 tons of bio-fermentation products annually, highlighting the company's technological upgrades and production capabilities in the bio-manufacturing sector [1]. Project Overview - Project Name: Annual production of 110,900 tons of bio-fermentation products - Construction Unit: Ningxia Zhongke Biological New Materials Co., Ltd. - Nature of Construction: Technological upgrade - Industry Category: C2710 Chemical raw materials and pharmaceutical manufacturing - Investment: 100.89 million yuan - Location: Shizuishan Economic and Technological Development Zone - Land Area: 387,309.18 m², utilizing existing facilities without new land acquisition [2]. Construction Scale - The project includes four flexible production lines: 1. **Long-chain dicarboxylic acid production line**: Annual capacity of 18,000 tons, producing various dicarboxylic acids [3]. 2. **Bio-fermentation functional products production line**: Annual capacity of 5,100 tons, including D-chiro-inositol, coenzyme Q10, and DHA algae oil [4]. 3. **Bio-food production line**: Annual capacity of 63,000 tons, producing calcium propionate and L-malic acid [5]. 4. **Amino acid products production line**: Annual capacity of 24,800 tons, producing various amino acids [6]. Technological Upgrade Scope - The upgrade encompasses fermentation workshops, extraction workshops, refining workshops, drying workshops, liquid bio-fertilizer workshops, tank areas, and power centers [7]. Company Background - Ningxia Zhongke Biological New Materials Co., Ltd. was established on June 2, 2017, with a registered capital of 1.3 billion yuan. The company is involved in the production of feed additives, food additives, fertilizers, and bio-based materials [8]. Financial Performance - The company reported revenue of 345 million yuan and a net loss of 539 million yuan during the reporting period. To address its debt crisis, the company entered pre-restructuring in May 2024, with government support extended until the end of 2024 [9]. - In the first quarter of 2025, the company achieved total revenue of 93.82 million yuan, a year-on-year increase of 74.08%, but still reported a net loss of 64.08 million yuan [11].

证券代码：600165 股票简称：ST 宁科 公告编号：临 2025-068 宁夏中科生物科技股份有限公司 关于重整及预重整事项的进展公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容及风险提示： ● 截至本公告披露日，宁夏中科生物科技股份有限公司（以下简称：公司 或宁科生物）除已披露的被申请重整及预重整、子公司宁夏中科生物新材料有 限公司（以下简称：中科新材）被法院裁定进行重整的事项外，未发生该事项 相关进展。 ● 中科新材进入重整程序，重整能否成功存在不确定性，如法院最终裁定 中科新材重整不成功，将存在被法院宣告破产的风险，公司将可能失去对中科 新材的控制权，存在失去对子公司的持股的风险，届时公司将无法再将中科新 材纳入合并报表，对公司资产、本期及期后利润产生一定的影响。但目前公司 仍为中科新材控股股东，对其后续重整过程及重整计划草案表决拥有表决权及 一定的决策权。此外，中科新材重整是基于公司及子公司整体协同重整、按统 一方案同时完成重整的整体计划及整体安排的基础上进行，并非孤立事件。如 按公司原定计划，公司能 ...